Reporting parties
Subject security
Symbol
MAZE
Shares outstanding
43,496,286 shares
Ownership signal
SEC evidence
Form type
SCHEDULE 13G/A
Filing time
14 Nov 2025, 16:04:27 UTC
Event date
30 Sep 2025
Previous filing
07 Feb 2025
SEC filing
View on sec.gov

Key filing fact

Foresite Capital Fund IV, L.P. disclosed 1.4% ownership in Maze Therapeutics, Inc. Common Stock, par value $0.001 (MAZE) on 30 Sep 2025.

Key facts

  • Foresite Capital Fund IV, L.P. filed SCHEDULE 13G/A for Maze Therapeutics, Inc. Common Stock, par value $0.001 (MAZE).
  • Disclosed ownership: 1.4%.
  • Date of event: 30 Sep 2025.

Change

  • Previous schedule filing date: 07 Feb 2025.
  • Current filing was accepted on 14 Nov 2025, 16:04.

Research use

  • This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
  • You can verify ownership claims directly against the original SEC filing.

Evidence

Backed by Schedule 13D/13G

Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.

See Original Filing

Reporting persons

Reporting managers (5)

Names, ownership, voting power, signatures, titles, and CIKs as disclosed in this Schedule 13D/G filing.

Name Ownership Shares Owned sole voting power shared voting power Signature Title CIK
Foresite Capital Fund IV, L.P. 1.2% 522,657 522,657 0 /s/ James Tananbaum James Tananbaum, Managing Member of the General Partner
Foresite Capital Management IV, LLC 1.2% 522,657 522,657 0 /s/ James Tananbaum James Tananbaum, Managing Member
Foresite Capital Fund V, L.P. 0.2% 86,291 86,291 0 /s/ James Tananbaum James Tananbaum, Managing Member of the General Partner
Foresite Capital Management V, LLC 0.2% 86,291 86,291 0 /s/ James Tananbaum James Tananbaum, Managing Member
James Tananbaum 1.4% 608,948 608,948 0 /s/ James Tananbaum James Tananbaum
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .